Research & Innovation in Anesthesia

Register      Login

VOLUME 7 , ISSUE 2 ( July-December, 2022 ) > List of Articles


Use of Remdesivir in severe COVID-19 Pregnant Patient

Neeraj Kumar, Saravanan Palavesam, Abhyuday Kumar, Chethan Vamshi, Ajeet Kumar

Keywords : COVID-19, High flow nasal cannula, Remdesivir, Third trimester

Citation Information : Kumar N, Palavesam S, Kumar A, Vamshi C, Kumar A. Use of Remdesivir in severe COVID-19 Pregnant Patient. Res Inno Anesth 2022; 7 (2):56-58.

DOI: 10.5005/jp-journals-10049-2016

License: CC BY-NC 4.0

Published Online: 22-10-2022

Copyright Statement:  Copyright © 2022; The Author(s).


The current coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on our healthcare system. Still, very little is known about the treatment modalities in the context of severe COVID in pregnancy. We describe a case of a 28-year-old patient who presented with severe COVID-19 and was admitted to our intensive care unit (ICU) in her third-trimester pregnancy with a progressive increase in oxygen requirement. Remdesivir may prove beneficial in reducing the inflammatory response and controlling the direct viral damage due to severe COVID-19 pneumonia resulting in favorable maternal and fetal outcomes.

PDF Share
  1. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69(44):1641–1647. DOI: 10.15585/mmwr.mm6944e3
  2. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies. Acta Obstet Gynecol Scand 2020;99(7):823–829. DOI: 10.1111/aogs.13867
  3. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020;295(20):6785–6797. DOI: 10.1074/jbc.RA120.013679
  4. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19-final report. N Engl J Med 2020;383(19):1813–1826. DOI: 10.1056/nejmoa2007764
  5. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020;383(19):1827–1837. DOI: 10.1056/NEJMoa2015301
  6. Lampejo T. Remdesivir for the treatment of COVID-19 in pregnancy. J Med Virol 2021;93(7):4114–4119. DOI: 10.1002/jmv.26986
  7. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381(24):2293–2303. DOI: 10.1056/NEJMoa1910993
  8. Burwick RM, Yawetz S, Stephenson KE, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019. Clin Infect Dis 2020;73(11):e3996–e4004. DOI: 10.1093/cid/ciaa1466
  9. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135(23):2033–2040. DOI: 10.1182/blood.2020006000
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.